- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period
This study looks at a new drug, SAR443820, for multiple sclerosis (MS). Researchers want to see if it lowers a marker in the blood called neurofilament, which can show nerve damage. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Multiple sclerosisSpain · Belgium · Germany - AuthorisedTherapeutic use (Phase IV)
Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group—ODYSSEY
This study, called ODYSSEY, checks if repeated use of certain MRI dyes over five years affects your movement or thinking. It compares people who get these dyes to those who don't. We want to understand if there are any long-term effects.
Italy · Germany · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
This study compares a new MRI dye, gadoquatrane, with existing dyes. It aims to see if the new dye helps doctors get clearer images of body parts (but not the brain or spine) and if it's safe to use.
For: Contrast enhancement in magnetic resonance imaging for assessment of non-central nervous system pathologyCzechia · Sweden · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)
This study is testing a new, lower-dose contrast dye called gadoquatrane for MRI brain scans. It wants to see if it's as good and safe as current higher-dose dyes at showing problems in the brain and spinal cord, like tumours or inflammation.
For: Contrast enhancement in magnetic resonance imaging for assessment of central nervous system pathologySweden · France · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization
This study looks into a new gene therapy, XC001, for people with severe heart disease who've had bypass surgery. It aims to see if XC001 can help improve heart function and reduce chest pain more than a dummy treatment.
For: Chronic angina and left ventricular dysfunction due to coronary artery disease that is considered high risk for incomplete revascularization via coronary artery bypass graftingNetherlands · Germany · Hungary